These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 30700250)

  • 21. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis.
    Zhang T; Pope JE
    Rheumatology (Oxford); 2017 Jul; 56(7):1144-1153. PubMed ID: 28379501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal.
    Stevenson M; Pandor A
    Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effectiveness of an enhanced invitation letter on uptake of National Health Service Health Checks in primary care: a pragmatic quasi-randomised controlled trial.
    Sallis A; Bunten A; Bonus A; James A; Chadborn T; Berry D
    BMC Fam Pract; 2016 Mar; 17():35. PubMed ID: 27009045
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of oral febuxostat for treatment of HLA-B*5801-negative gout: a randomized, open-label, multicentre, allopurinol-controlled study.
    Yu KH; Lai JH; Hsu PN; Chen DY; Chen CJ; Lin HY
    Scand J Rheumatol; 2016 Jul; 45(4):304-11. PubMed ID: 26771445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
    Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
    Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
    Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A model-based meta-analysis to compare urate-lowering response rate of febuxostat and allopurinol in gout patient].
    Sun Y; Li L; Zhou TY; Lu W
    Yao Xue Xue Bao; 2014 Dec; 49(12):1674-83. PubMed ID: 25920196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Achieving serum urate goal: a comparative effectiveness study between allopurinol and febuxostat.
    Hatoum H; Khanna D; Lin SJ; Akhras KS; Shiozawa A; Khanna P
    Postgrad Med; 2014 Mar; 126(2):65-75. PubMed ID: 24685969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Effectiveness Analysis of Lesinurad/Allopurinol Versus Febuxostat for the Management of Gout/Hyperuricemia in Italy.
    Ruggeri M; Basile M; Drago C; Rolli FR; Cicchetti A
    Pharmacoeconomics; 2018 May; 36(5):625-636. PubMed ID: 29557073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of personalised versus non-personalised study invitations on recruitment within the ENGAGE feasibility trial: an embedded randomised controlled recruitment trial.
    Thiblin E; Woodford J; Öhman M; von Essen L
    BMC Med Res Methodol; 2022 Mar; 22(1):65. PubMed ID: 35249543
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of febuxostat in patients with gout in Spain.
    Perez-Ruiz F; Díaz-Torné C; Carcedo D
    J Med Econ; 2016 Jun; 19(6):604-10. PubMed ID: 26855041
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR; Becker MA; Wortmann RL; Macdonald PA; Hunt B; Streit J; Lademacher C; Joseph-Ridge N
    Arthritis Rheum; 2008 Nov; 59(11):1540-8. PubMed ID: 18975369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reinvitation to screening colonoscopy: a randomized-controlled trial of reminding letter and invitation to educational meeting on attendance in nonresponders to initial invitation to screening colonoscopy (REINVITE).
    Pisera M; Kaminski MF; Kraszewska E; Rupinski M; Regula J
    Eur J Gastroenterol Hepatol; 2016 May; 28(5):538-42. PubMed ID: 26967693
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of two different participant information sheets on recruitment to a falls trial: An embedded randomised recruitment trial.
    Witham MD; Band MM; Price RJG; Fulton RL; Clarke CL; Donnan PT; Soiza RL; Cvoro V
    Clin Trials; 2018 Dec; 15(6):551-556. PubMed ID: 30260246
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of Recruitment Methods on Response Rate in a Web-Based Study for Primary Care Physicians: Factorial Randomized Controlled Trial.
    So R; Shinohara K; Aoki T; Tsujimoto Y; Suganuma AM; Furukawa TA
    J Med Internet Res; 2018 Feb; 20(2):e28. PubMed ID: 29422450
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A systematic review and meta-analysis on the safety and efficacy of febuxostat versus allopurinol in chronic gout.
    Faruque LI; Ehteshami-Afshar A; Wiebe N; Tjosvold L; Homik J; Tonelli M
    Semin Arthritis Rheum; 2013 Dec; 43(3):367-75. PubMed ID: 24326033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of a DVD to provide dietary and lifestyle information to pregnant women who are overweight or obese: a nested randomised trial.
    Szmeja MA; Cramp C; Grivell RM; Deussen AR; Yelland LN; Dodd JM
    BMC Pregnancy Childbirth; 2014 Dec; 14():409. PubMed ID: 25495459
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Febuxostat in the management of gout: a cost-effectiveness analysis.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    J Med Econ; 2016; 19(3):265-76. PubMed ID: 26535593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Budget Impact of Increased Use of Febuxostat in the Management of Gout: A US Health Plan Managed Care Pharmacy and Medical Costs Perspective.
    Smolen LJ; Gahn JC; Mitri G; Shiozawa A
    Clin Ther; 2016 Jul; 38(7):1710-25. PubMed ID: 27269247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of febuxostat for prevention of tumor lysis syndrome in patients with malignant tumors receiving chemotherapy: a phase III, randomized, multi-center trial comparing febuxostat and allopurinol.
    Tamura K; Kawai Y; Kiguchi T; Okamoto M; Kaneko M; Maemondo M; Gemba K; Fujimaki K; Kirito K; Goto T; Fujisaki T; Takeda K; Nakajima A; Ueda T
    Int J Clin Oncol; 2016 Oct; 21(5):996-1003. PubMed ID: 27017611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.